Basroparib is under clinical development by ST Pharm and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I drugs for Colorectal Cancer have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Basroparib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Basroparib overview
Basroparib (STP-061002) is under development for the treatment of solid tumors including colorectal cancer, non-small cell lung cancer, gastric cancer, renal cell cancer and hepatocellular carcinoma. The drug candidate is administered through oral route in the form of capsule. It acts by targeting tankyrase 1 and 2 (TNKS).
ST Pharm overview
ST Pharm offers manufacturing services for active pharmaceutical ingredients and intermediates. It provides nucleoside-based active pharmaceuticals in various antiviral drug applications. ST Pharm’s pipeline products include pirmitegravir traets human immunodeficiency virus (HIV) infections (AIDS) and Basroparib targets kidney cancer, non-small cell lung cancer, colorectal cancer gastric cancer and hepatocellular carcinoma.
For a complete picture of Basroparib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.